ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................J0009013-ENDS014729128EUROPEAN PATENT APPLICATIONA320260708EP26160800.420140207enenen201361769596 P20130226US2026070820262820260422202617A61K 35/28 20150101AFI20260603BHEP A61P 37/06 20060101ALI20260603BHEP A61K 35/28 20130101 LI20150115BHEP A61K2300/00 20130101 LI20150115BHEP A61K 35/28 20130101 LI20140828BHEP A61K 31/365 20130101 FI20170420BHEP A61K 31/436 20130101 LI20170420BHEP A61K 31/573 20130101 LI20170420BHEP A61P 13/12 20180101 LI20200319BHEP A61P 37/06 20180101 LI20200331BHEP C12N 5/0636 20130101 LI20240322RHEP C12N 5/0634 20130101 LI20240322RHEP A61K2239/31 20230501 LA20240322RHEP A61K2239/38 20230501 LA20240322RHEP A61K 40/10 20250101 LI20250101RHEP A61K 40/22 20250101 LI20250101RHEP A61K 40/11 20250101 LI20250101RHEP A61K 40/418 20250101 LI20250101RHEP deKOMBINIERTE ORGAN- UND HÄMATOPOIETISCHE ZELLEN FÜR TRANSPLANTATIONSTOLERANZenCOMBINED ORGAN AND HEMATOPOIETIC CELLS FOR TRANSPLANTATION TOLERANCE OF GRAFTSfrORGANE ET CELLULES HEMATOPOIETIQUES COMBINES POUR TOLERANCE AUX TRANSPLANTATIONS DE GREFFES120208694.838047352020111914756899.2296143120140207The Board of Trustees of the Leland Stanford Junior University102127921P103449EP53Office of the General Counsel P.O. Box 20386 Building 170, Third Floor, Main QuadStanford, CA 94305-2038USSTROBER, SamuelStanford, 94305USLOWSKY, RobertStanford, 94305USAvidity IP101660475Future Business Centre Cambridge Campus Kings Hedges RoadCambridge CB4 2HYGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTR20260708202628

Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

P103449EP53EP26160800.4The Board of Trustees of the Leland StanfordJunior UniversityDH20260610A61KA61PWO2011068829A1UNIV LELAND STANFORD JUNIOR [US]; SARWAL MINNIE M [US]; LI LI [US]; ST20110609X1-15* page 25, lines 15-33page 26, lines 9-13page 27, lines 9-15page 28, lines 14-28page 29, line 8-page 30, line 9page 33, line 23-page 34, line 28page 27, lines 25-32;example 1; table 2 *WO03012060A2JEWISH HOSPITAL HEALTHCARE SER [US]; ILDSTAD SUZANNE T [US]; WHELTON P20030213A1-15* paragraphs [0025] - [0037], [0052], [0056], [0061], [0066], [0123] - [0139]; claim claims; figure 1 *
J. D. SCANDLING ET ALTolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell TransplantsAMERICAN JOURNAL OF TRANSPLANTATIONDK2012030812510.1111/j.1600-6143.2012.03992.x1600-613511331145XP055227707
A1-15page 1134, left column, paragraphs 2-4* abstract; table 1 *
SCANDLING J D ET ALTOLERANCE AND CHIMERISM AFTER RENAL AND HEMATOPOIETIC-CELL TRANSPLANTATIONNEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM, MASSACHUSETTS MEDICAL SOCIETY, US20080124358410.1056/NEJMOA0741911533-4406362368XP002562462
A1-15page 363, right column, paragraph 2page 363, left column, paragraph 1* abstract *WO0045842A2GEN HOSPITAL CORP [US]; SYKES MEGAN [US]20000810A1-15* examples 1-2 *Habedanck, RobertThe Hague20260527WO2011068829A120110609CA2782803A120110609EP2507630A120121010EP3185013A220170628US2012329668A120121227US2016376653A120161229WO2011068829A120110609WO03012060A220030213AU2002322857A120030217EP1423503A220040602US2005118142A120050602WO03012060A220030213WO0045842A220000810AU2980900A20000825US2002159999A120021031US2008175850A120080724US2010074902A120100325WO0045842A220000810